GENE ONLINE|News &
Opinion
Blog

2021-11-25| Special

Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

by Sahana Shankar
Share To
Cancer cells escape identification and neutralization by the immune system by multiple strategies. One of them is ligand-mediated deactivation of immune checkpoints, which spurred the advent of cancer immunotherapy with anti-PD1.

However, not all patients respond well to immunotherapy, suggesting other immune evasion pathways in cancers. Researchers from MIT and Brigham and Women’s Hospital employed nanotechnology to unravel a novel mechanism of cancer cells to attack and suppress immune cells.

Co-culture of breast cancer cells with effector T cells and subsequent high-resolution imaging showed a physical linkage between cancer cells and nearby T cells with an average width of 100-1000nm. These nanotubes were composed of actin and other cytoskeletal proteins, suggesting that they may be involved in intercellular transport.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top